Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
“Headquarters Involvement Clear” in Access to Patient Medical Charts by Bayer Sales Reps: Attorney for Whistleblower
Bayer Yakuhin and the health ministry should investigate the entire issue of the survey scandal surrounding Bayer Yakuhin’s anticoagulant Xarelto (rivaroxaban), an attorney representing the company’s sales rep who reported the scandal said on April 19. The scandal emerged last…
To read the full story
Related Article
- Bayer, Employee Reach Settlement over Xarelto Scandal
July 28, 2022
- High Court Verdict for Bayer Employee Damage Suit Set for Sept. 7, Settlement Eyed Too
July 5, 2022
- Bayer Employee Loses in Damage Suit over Xarelto Scandal
February 15, 2022
- Bayer Flatly Denies Its Employee’s Allegations in 2nd Oral Proceedings for Damage Suit
July 18, 2019
- Xarelto Issue Morally Questionable, but Does Not Constitute Misleading Ads Banned under Law: MHLW Officials
April 20, 2017
- Sales Rep and Doctor at Center of Xarelto Survey Scandal Conflict over “Patient Consent”
April 14, 2017
- Bayer Apologizes for Employees’ “Improper” Involvement in Xarelto Survey, Whistleblower Says He Browsed Charts for over 200 Patients
April 12, 2017
BUSINESS
- Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026
- Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
February 17, 2026
- Rakuten to Launch Japan PI of RM-0256 Photoimmunotherapy in April-June
February 17, 2026
- Kidswell, Treehill to Form US Firm for Cell Therapy Development
February 17, 2026
- Ono’s Velexbru Accepted for FDA Review in PCNSL
February 17, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…